Slide 1: Phase 2 ELEKTRA Trial Positive Topline Results
Phase 2 ELEKTRA Trial Positive Topline Results August 25, 2020 ©2020 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED Exhibit 99.2
Slide 2: Disclaimers and Forward-Looking Statements
Disclaimers and Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “believe,” “expect,” “plan,” “anticipate” and similar expressions (as well as other words or expre
Slide 3: Advanced Pipeline Focused on Rare Neurological Diseases
Advanced Pipeline Focused on Rare Neurological Diseases PRODUCT CANDIDATE INDICATION RESEARCH PRECLINICAL PHASE 1 PHASE 2 PHASE 3 OV101 δ-selective GABAA receptor agonist Angelman Syndrome Fragile X OV935 CH24H inhibitor Dravet Syndrome (DS) / Lennox-Gastaut Syndrome (LGS) CDKL5 Deficiency Disorder
Slide 4: Today's Discussion – Focus on ELEKTRA and ENDYMION
PRODUCT CANDIDATE INDICATION RESEARCH PRECLINICAL PHASE 1 PHASE 2 PHASE 3 OV101 δ-selective GABAA receptor agonist Angelman Syndrome Fragile X OV935 CH24H inhibitor Dravet Syndrome (DS) / Lennox-Gastaut Syndrome (LGS) CDKL5 Deficiency Disorder / Dup15q Syndrome OV329 GABA aminotransferase inhibitor
Slide 5: Soticlestat (OV935/TAK-935)
Soticlestat (OV935/TAK-935) ©2020 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED ELEKTRA and ENDYMION are part of a broad-based clinical development program to examine multiple types of epilepsy: Ovid:Takeda “One Team” Alliance – entered into January 2017 Ovid purchased a 50% share in soticlestat; 50:
Slide 6: Primary Endpoint Achieved: Statistically significant reduction of seizures
Primary Endpoint Achieved: Statistically significant reduction of seizures from baseline compared to placebo (P=0.0007) in the maintenance period for combined Dravet syndrome and Lennox-Gastaut syndrome study population Phase 2 ELEKTRA Trial: Topline Results in Dravet Syndrome (DS) & Lennox-Gastaut
Slide 7: Soticlestat Targets Cholesterol Metabolism in the Brain
Soticlestat Targets Cholesterol Metabolism in the Brain Reduced 24HC levels cause reduced glutamatergic signaling and modulates glial function, resulting in reduced inflammation Cholesterol-24-Hydroxylase metabolizes cholesterol and generates 24 Hydroxycholesterol (24HC) Soticlestat has the potentia
Slide 8: Soticlestat is a Potent, Selective, Brain-Penetrating CH24H Inhibitor
Reduced 24HC levels cause reduced glutamatergic signaling and modulates glial function, resulting in reduced inflammation Soticlestat inhibits CH24H, resulting in a dose-dependent reduction in 24HC levels Soticlestat has the potential to reduce seizure susceptibility and improve seizure control Soti
Slide 9: Dravet Syndrome and Lennox-Gastaut Syndrome are Different Disorders with Few Approved Treatments
Dravet Syndrome and Lennox-Gastaut Syndrome are Different Disorders with Few Approved Treatments Dravet Syndrome (DS) Lennox-Gastaut Syndrome (LGS) Etiology 80% have mutations in Scn1a gene Heterogeneous condition which can be caused by any number of reasons including: several gene mutations, perina
Slide 10: Phase 2 ELEKTRA Trial Design
Key Inclusion Criteria Aged ≥2 and ≤17 years Clinical diagnosis of DS or LGS Failed at least ≥2 AEDs Currently taking 1–4 AEDs at a stable dose Minimum of at least 3 convulsive (DS) or 4 drop (LGS) seizures during a minimum 4-wk prospective baseline Trial Design Global, multicenter, randomized, doub
Slide 11: Patient Baseline Demographics & Disease Characteristics
A total of 141 patients were enrolled and 126 completed the study Modified intent to treat (mITT) analysis of 139 patients was performed to evaluate the efficacy endpoints1 Patient Baseline Demographics & Disease Characteristics ©2020 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED DS LGS Soticlestat (
Slide 12: ELEKTRA Efficacy Endpoints
ELEKTRA Efficacy Endpoints ©2020 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED Primary Efficacy Endpoint Median percent change from baseline in seizure frequency (based only on convulsive seizures for DS patients and drop seizures for LGS patients) during 12-week maintenance period Secondary Efficacy
Slide 13: Efficacy Endpoint Results: DS & LGS
Efficacy Endpoint Results: DS & LGS ©2020 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED (Primary Endpoint) Efficacy Set (Secondary Endpoint) mITT (2) (2) 1 Rank Transformed ANCOVA adjusting for baseline seizure frequency and protocl amendment cohort 2Hodges-Lehmann Estimation of the median in treatme
Slide 14: Efficacy Endpoint Results (mITT): DS Cohort (Convulsive Seizures)
Efficacy Endpoint Results (mITT): DS Cohort (Convulsive Seizures) ©2020 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED (2) (2) 1 Rank Transformed ANCOVA adjusting for baseline seizure frequency and protocol amendment cohort 2Hodges-Lehmann Estimation of the median in treatment difference (percent chan
Slide 15: Efficacy Endpoint Results (mITT): LGS Cohort (Drop Seizures)
Efficacy Endpoint Results (mITT): LGS Cohort (Drop Seizures) ©2020 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED (2) (2) 1 Rank Transformed ANCOVA adjusting for baseline seizure frequency and protocol amendment cohort 2Hodges-Lehmann Estimation of the median in treatment difference (percent change fr
Slide 16: Proportion of Responders During Full Treatment Period
Proportion of Responders During Full Treatment Period ≥50% reduction in seizure frequency from baseline ©2020 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED DS LGS % reduction from baseline in convulsive seizure frequency % reduction from baseline in drop seizure frequency
Slide 17: Favorable Safety Profile Consistent with Previous Studies
NOTE: TEAEs are the adverse events reported following randomization and initial dose of study drug Favorable Safety Profile Consistent with Previous Studies No new safety signals identified ©2020 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED Soticlestat (N=71) n (%) Placebo (N=70) n (%) Total (N=141)
Slide 18: Clinical Global Impression of Change (CGI-C; Investigator) Responses at Last Visit
Clinical Global Impression of Change (CGI-C; Investigator) Responses at Last Visit ©2020 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED m= the number of subjects with non-missing value at the specific analysis visit in the modified intent-to-treat analysis set
Slide 19: ENDYMION: DS Cohort – Positive Response in Placebo Crossover
ENDYMION: DS Cohort – Positive Response in Placebo Crossover and Continued Efficacy in Soticlestat Patients ©2020 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED Median Percent Change from ELEKTRA Study Baseline in 28-days Convulsive Seizure Frequency Soticlestat Placebo 25 0 -25 -50 -75 -100 Overall T
Slide 20: ENDYMION: LGS Cohort – Reduction in Drop Seizure Frequency
ENDYMION: LGS Cohort – Reduction in Drop Seizure Frequency in Placebo Crossover and Continued Effect in Soticlestat Patients ©2020 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 50 25 0 -25 -50 -75 Overall Treatment Period in ELEKTRA Month 1 Month 3 Month 6 25 25 32 25 29 15 20 n = Median Percent Chan
Slide 21: Summary and Next Steps
Summary and Next Steps ©2020 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED ELEKTRA Summary ELEKTRA study achieved its primary endpoint with high statistical significance (P=0.0007) Strong efficacy results in Dravet syndrome with a 46% median difference from placebo in convulsive seizure frequency red
Slide 22: 2020: A Transformative Year for Ovid
2020: A Transformative Year for Ovid ©2020 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED OV101: Fragile X syndrome – Phase 2 ROCKET trial positive topline data 4Q 2020: Angelman syndrome - Pivotal Phase 3 NEPTUNE trial topline data Soticlestat: ARCADE initial data ELEKTRA topline data, ENDYMION data
Slide 23: Q&A
Q&A ©2020 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED